REG - Competition and Mkts - Merger Update : Stryker/Wright

StrykerAnnouncement

04/11/2020 11:46

RNS Number : 2273E
  
Competition and Markets Authority
  
04 November 2020
  
 

Medical device supplier resolves CMA concerns
The CMA has accepted a proposal from Stryker to sell its business in the UK total ankle prostheses market to resolve competition concerns.
Stryker Corporation (Stryker) and Wright Medical Group N.V. (Wright) both manufacture a range of orthopaedic products for patients requiring implants in their feet, ankles and hands. Following an initial Phase 1 investigation in June, the Competition and Markets Authority (CMA) was concerned that the £4.2 billion merger between the 2 companies would have a negative impact on vulnerable patients in the UK who need ankle replacements.
Stryker has now offered to sell off its global total ankle replacement product and assets to Colfax Corporation (Colfax) who will incorporate this into their subsidiary, DJO Global. The CMA is satisfied that this full structural divestment will address its competition concerns. 
The CMA has been co-operating closely with the US Federal Trade Commission (FTC), which has also been reviewing the merger. In August, the CMA announced that it had agreed to extend its consideration of an acceptable divestment package in order to align with the FTC's timing and ensure that the divestment package would be acceptable in both UK and US jurisdictions.
Joel Bamford, CMA Senior Director of Mergers, said:
 "Competition in the medical device sector is vital to improve patient treatments, particularly for medical products designed to help vulnerable people suffering from serious degenerative conditions.
"The close cooperation with the FTC's inquiry and early engagement with both companies has enabled Stryker to address our important concerns about this deal and has led to an outcome that works on a global basis."
The full text of the CMA decision will be published shortly on the Stryker/Wright merger inquiry case page.
For media enquiries, contact the CMA press office on 020 3738 6460 or press@cma.gov.uk. 
 
 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MERBIBLTMTTMMBM